An Antioxidant Response Phenotype Shared between Hereditary and Sporadic Type 2 Papillary Renal Cell Carcinoma

Cancer Cell

Volumn 20, Issue 4, 2011, Pages 511-523

  Ooi, Aikseng ^a   Wong, Jing Chii ^b   Petillo, David ^a   Roossien, Douglas ^a   Perrier Trudova, Victoria ^a,c   Whitten, Douglas ^d   Min, Bernice Wong Hui ^b   Tan, Min Han ^b   Zhang, Zhongfa ^a   Yang, Ximing J ^e   Zhou, Ming ^f   Gardie, Betty ^c   Molinié, Vincent ^c   Richard, Stéphane ^c   Tan, Puay Hoon ^g   Teh, Bin Tean ^a,b   Furge, Kyle A ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d MICHIGAN STATE UNIVERSITY   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALDO KETO REDUCTASE FAMILY 1 MEMBER B10; CIS ACTING ELEMENT; FUMARATE HYDRATASE; FUMARIC ACID; OXIDOREDUCTASE; PROTEIN; PROTEIN MEN2A; SUCCINATE DEHYDROGENASE; TRANSCRIPTION FACTOR NRF1; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ANGIOGENESIS; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; CANCER CELL CULTURE; CLEAR CELL CARCINOMA; CONTROLLED STUDY; FAMILIAL CANCER; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; LOSS OF FUNCTION MUTATION; NUCLEOTIDE SEQUENCE; NULL ALLELE; PAPILLARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPORADIC CANCER; TUMOR DIFFERENTIATION; TYPE 2 PAPILLARY RENAL CELL CARCINOMA; UPREGULATION;

EID: 80054772589     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2011.08.024     Document Type: Article

References (66)

1. Alam N.A., Rowan A.J., Wortham N.C., Pollard P.J., Mitchell M., Tyrer J.P., Barclay E., Calonje E., Manek S., Adams S.J., et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum. Mol. Genet. 2003, 12:1241-1252.
2. Alderson N.L., Wang Y., Blatnik M., Frizzell N., Walla M.D., Lyons T.J., Alt N., Carson J.A., Nagai R., Thorpe S.R., Baynes J.W. S-(2-Succinyl)cysteine: a novel chemical modification of tissue proteins by a Krebs cycle intermediate. Arch. Biochem. Biophys. 2006, 450:1-8.
3. Bellacosa A., Godwin A.K., Peri S., Devarajan K., Caretti E., Vanderveer L., Bove B., Slater C., Zhou Y., Daly M., et al. Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations. Cancer Prev Res (Phila) 2010, 3:48-61.
4. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 1995, 57:289-300.
5. Blatnik M., Thorpe S.R., Baynes J.W. Succination of proteins by fumarate: mechanism of inactivation of glyceraldehyde-3-phosphate dehydrogenase in diabetes. Ann. N Y Acad. Sci. 2008, 1126:272-275.
6. Carvajal-Carmona L.G., Alam N.A., Pollard P.J., Jones A.M., Barclay E., Wortham N., Pignatelli M., Freeman A., Pomplun S., Ellis I., et al. Adult leydig cell tumors of the testis caused by germline fumarate hydratase mutations. J. Clin. Endocrinol. Metab. 2006, 91:3071-3075.
7. Chan K., Han X.D., Kan Y.W. An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc. Natl. Acad. Sci. USA 2001, 98:4611-4616.
8. Dahia P.L., Ross K.N., Wright M.E., Hayashida C.Y., Santagata S., Barontini M., Kung A.L., Sanso G., Powers J.F., Tischler A.S., et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet. 2005, 1:72-80.
9. Frizzell N., Lima M., Baynes J.W. Succination of proteins in diabetes. Free Radic. Res. 2010, 45:101-109.
10. Frizzell N., Rajesh M., Jepson M.J., Nagai R., Carson J.A., Thorpe S.R., Baynes J.W. Succination of thiol groups in adipose tissue proteins in diabetes: succination inhibits polymerization and secretion of adiponectin. J. Biol. Chem. 2009, 284:25772-25781.
11. Furge K.A., Tan M.H., Dykema K., Kort E., Stadler W., Yao X., Zhou M., Teh B.T. Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling. Oncogene 2007, 26:1346-1350.
12. Furukawa M., Xiong Y. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol. Cell. Biol. 2005, 25:162-171.
13. Gao L., Wang J., Sekhar K.R., Yin H., Yared N.F., Schneider S.N., Sasi S., Dalton T.P., Anderson M.E., Chan J.Y., et al. Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Cullin3. J. Biol. Chem. 2007, 282:2529-2537.
14. Hayes J.D., McMahon M. Molecular basis for the contribution of the antioxidant responsive element to cancer chemoprevention. Cancer Lett. 2001, 174:103-113.
15. Holmgren A., Lu J. Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochem. Biophys. Res. Commun. 2010, 396:120-124.
16. Hsieh T.C., Lu X., Wang Z., Wu J.M. Induction of quinone reductase NQO1 by resveratrol in human K562 cells involves the antioxidant response element ARE and is accompanied by nuclear translocation of transcription factor Nrf2. Med. Chem. 2006, 2:275-285.
17. Huang Y.W., Jansen R.A., Fabbri E., Potter D., Liyanarachchi S., Chan M.W., Liu J.C., Crijns A.P., Brown R., Nephew K.P., et al. Identification of candidate epigenetic biomarkers for ovarian cancer detection. Oncol. Rep. 2009, 22:853-861.
18. Huang Y.W., Luo J., Weng Y.I., Mutch D.G., Goodfellow P.J., Miller D.S., Huang T.H. Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas. Gynecol. Oncol. 2010, 117:239-247.
19. Hübner R.H., Schwartz J.D., De Bishnu P., Ferris B., Omberg L., Mezey J.G., Hackett N.R., Crystal R.G. Coordinate control of expression of Nrf2-modulated genes in the human small airway epithelium is highly responsive to cigarette smoking. Mol. Med. 2009, 15:203-219.
20. Isaacs J.S., Jung Y.J., Mole D.R., Lee S., Torres-Cabala C., Chung Y.L., Merino M., Trepel J., Zbar B., Toro J., et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005, 8:143-153.
21. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., Salic A., Asara J.M., Lane W.S., Kaelin W.G. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001, 292:464-468.
22. Kashkar H., Deggerich A., Seeger J.M., Yazdanpanah B., Wiegmann K., Haubert D., Pongratz C., Krönke M. NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs. Blood 2007, 109:3982-3988.
23. Kiuru M., Launonen V. Hereditary leiomyomatosis and renal cell cancer (HLRCC). Curr. Mol. Med. 2004, 4:869-875.
24. Koivunen P., Hirsilä M., Remes A.M., Hassinen I.E., Kivirikko K.I., Myllyharju J. Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J. Biol. Chem. 2007, 282:4524-4532.
25. Koshikawa N., Hayashi J., Nakagawara A., Takenaga K. Reactive oxygen species-generating mitochondrial DNA mutation up-regulates hypoxia-inducible factor-1alpha gene transcription via phosphatidylinositol 3-kinase-Akt/protein kinase C/histone deacetylase pathway. J. Biol. Chem. 2009, 284:33185-33194.
26. Kwak M.K., Kensler T.W., Casero R.A. Induction of phase 2 enzymes by serum oxidized polyamines through activation of Nrf2: effect of the polyamine metabolite acrolein. Biochem. Biophys. Res. Commun. 2003, 305:662-670.
27. Lau A., Villeneuve N.F., Sun Z., Wong P.K., Zhang D.D. Dual roles of Nrf2 in cancer. Pharmacol. Res. 2008, 58:262-270.
28. Launonen V., Vierimaa O., Kiuru M., Isola J., Roth S., Pukkala E., Sistonen P., Herva R., Aaltonen L.A. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc. Natl. Acad. Sci. USA 2001, 98:3387-3392.
29. Lee D.F., Kuo H.P., Liu M., Chou C.K., Xia W., Du Y., Shen J., Chen C.T., Huo L., Hsu M.C., et al. KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. Mol. Cell 2009, 36:131-140.
30. Lehtonen H.J., Kiuru M., Ylisaukko-Oja S.K., Salovaara R., Herva R., Koivisto P.A., Vierimaa O., Aittomäki K., Pukkala E., Launonen V., Aaltonen L.A. Increased risk of cancer in patients with fumarate hydratase germline mutation. J. Med. Genet. 2006, 43:523-526.
31. Linehan W.M., Bratslavsky G., Pinto P.A., Schmidt L.S., Neckers L., Bottaro D.P., Srinivasan R. Molecular diagnosis and therapy of kidney cancer. Annu. Rev. Med. 2010, 61:329-343.
32. Linehan W.M., Pinto P.A., Srinivasan R., Merino M., Choyke P., Choyke L., Coleman J., Toro J., Glenn G., Vocke C., et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin. Cancer Res. 2007, 13:671s-679s.
33. MacLeod A.K., McMahon M., Plummer S.M., Higgins L.G., Penning T.M., Igarashi K., Hayes J.D. Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds. Carcinogenesis 2009, 30:1571-1580.
34. Malec V., Gottschald O.R., Li S., Rose F., Seeger W., Hänze J. HIF-1 alpha signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells. Free Radic. Biol. Med. 2010, 48:1626-1635.
35. McMahon M., Itoh K., Yamamoto M., Chanas S.A., Henderson C.J., McLellan L.I., Wolf C.R., Cavin C., Hayes J.D. The Cap'n'Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res. 2001, 61:3299-3307.
36. Molina A.M., Feldman D.R., Ginsberg M.S., Kroog G., Tickoo S.K., Jia X., Georges M., Patil S., Baum M.S., Reuter V.E., Motzer R.J. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest. New Drugs. 2010, [Epub ahead of print].
37. Nagai R., Brock J.W., Blatnik M., Baatz J.E., Bethard J., Walla M.D., Thorpe S.R., Baynes J.W., Frizzell N. Succination of protein thiols during adipocyte maturation: a biomarker of mitochondrial stress. J. Biol. Chem. 2007, 282:34219-34228.
38. Nioi P., Nguyen T. A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem. Biophys. Res. Commun. 2007, 362:816-821.
39. O'Flaherty L., Adam J., Heather L.C., Zhdanov A.V., Chung Y.L., Miranda M.X., Croft J., Olpin S., Clarke K., Pugh C.W., et al. Dysregulation of hypoxia pathways in fumarate hydratase-deficient cells is independent of defective mitochondrial metabolism. Hum. Mol. Genet. 2010, 19:3844-3851.
40. Ohta T., Iijima K., Miyamoto M., Nakahara I., Tanaka H., Ohtsuji M., Suzuki T., Kobayashi A., Yokota J., Sakiyama T., et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res. 2008, 68:1303-1309.
41. Ohtsuji M., Katsuoka F., Kobayashi A., Aburatani H., Hayes J.D., Yamamoto M. Nrf1 and Nrf2 play distinct roles in activation of antioxidant response element-dependent genes. J. Biol. Chem. 2008, 283:33554-33562.
42. Pae H.O., Oh G.S., Lee B.S., Rim J.S., Kim Y.M., Chung H.T. 3-Hydroxyanthranilic acid, one of L-tryptophan metabolites, inhibits monocyte chemoattractant protein-1 secretion and vascular cell adhesion molecule-1 expression via heme oxygenase-1 induction in human umbilical vein endothelial cells. Atherosclerosis 2006, 187:274-284.
43. Pollard P., Wortham N., Barclay E., Alam A., Elia G., Manek S., Poulsom R., Tomlinson I. Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome. J. Pathol. 2005, 205:41-49.
44. Pollard P.J., Brière J.J., Alam N.A., Barwell J., Barclay E., Wortham N.C., Hunt T., Mitchell M., Olpin S., Moat S.J., et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet. 2005, 14:2231-2239.
45. Pollard P.J., El-Bahrawy M., Poulsom R., Elia G., Killick P., Kelly G., Hunt T., Jeffery R., Seedhar P., Barwell J., et al. Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. J. Clin. Endocrinol. Metab. 2006, 91:4593-4598.
46. Rachakonda G., Xiong Y., Sekhar K.R., Stamer S.L., Liebler D.C., Freeman M.L. Covalent modification at Cys151 dissociates the electrophile sensor Keap1 from the ubiquitin ligase CUL3. Chem. Res. Toxicol. 2008, 21:705-710.
47. Russo P., O'Regan S. Visceral pathology of hereditary tyrosinemia type I. Am. J. Hum. Genet. 1990, 47:317-324.
48. Sakurai A., Nishimoto M., Himeno S., Imura N., Tsujimoto M., Kunimoto M., Hara S. Transcriptional regulation of thioredoxin reductase 1 expression by cadmium in vascular endothelial cells: role of NF-E2-related factor-2. J. Cell. Physiol. 2005, 203:529-537.
49. Sango K., Suzuki T., Yanagisawa H., Takaku S., Hirooka H., Tamura M., Watabe K. High glucose-induced activation of the polyol pathway and changes of gene expression profiles in immortalized adult mouse Schwann cells IMS32. J. Neurochem. 2006, 98:446-458.
50. Shibata T., Ohta T., Tong K.I., Kokubu A., Odogawa R., Tsuta K., Asamura H., Yamamoto M., Hirohashi S. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc. Natl. Acad. Sci. USA 2008, 105:13568-13573.
51. Singh A., Misra V., Thimmulappa R.K., Lee H., Ames S., Hoque M.O., Herman J.G., Baylin S.B., Sidransky D., Gabrielson E., et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 2006, 3:e420.
52. Siow R.C., Ishii T., Mann G.E. Modulation of antioxidant gene expression by 4-hydroxynonenal: atheroprotective role of the Nrf2/ARE transcription pathway. Redox Rep. 2007, 12:11-15.
53. Smyth G.K. Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions using R and Bioconductor 2005, 397-420. Springer, New York. R. Gentleman, V. Carey, S. Dudoit, R.A. Irizarry, W. Huber (Eds.).
54. Sourbier C., Valera-Romero V., Giubellino A., Yang Y., Sudarshan S., Neckers L., Linehan W.M. Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma. Cell Cycle 2010, 9:4183-4189.
55. Spencer S.R., Wilczak C.A., Talalay P. Induction of glutathione transferases and NAD(P)H:quinone reductase by fumaric acid derivatives in rodent cells and tissues. Cancer Res. 1990, 50:7871-7875.
56. Sudarshan S., Sourbier C., Kong H.S., Block K., Valera Romero V.A., Yang Y., Galindo C., Mollapour M., Scroggins B., Goode N., et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol. Cell. Biol. 2009, 29:4080-4090.
57. Tomlinson I.P., Alam N.A., Rowan A.J., Barclay E., Jaeger E.E., Kelsell D., Leigh I., Gorman P., Lamlum H., Rahman S., et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 2002, 30:406-410. Multiple Leiomyoma Consortium.
58. Vanharanta S., Buchta M., McWhinney S.R., Virta S.K., Peçzkowska M., Morrison C.D., Lehtonen R., Januszewicz A., Järvinen H., Juhola M., et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am. J. Hum. Genet. 2004, 74:153-159.
59. Vanharanta S., Pollard P.J., Lehtonen H.J., Laiho P., Sjöberg J., Leminen A., Aittomäki K., Arola J., Kruhoffer M., Orntoft T.F., et al. Distinct expression profile in fumarate-hydratase-deficient uterine fibroids. Hum. Mol. Genet. 2006, 15:97-103.
60. Venugopal R., Jaiswal A.K. Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene 1998, 17:3145-3156.
61. Wang R., An J., Ji F., Jiao H., Sun H., Zhou D. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem. Biophys. Res. Commun. 2008, 373:151-154.
62. Wang R., Kern J.T., Goodfriend T.L., Ball D.L., Luesch H. Activation of the antioxidant response element by specific oxidized metabolites of linoleic acid. Prostaglandins Leukot. Essent. Fatty Acids 2009, 81:53-59.
63. Yang Y., Valera V.A., Padilla-Nash H.M., Sourbier C., Vocke C.D., Vira M.A., Abu-Asab M.S., Bratslavsky G., Tsokos M., Merino M.J., et al. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet. Cytogenet. 2010, 196:45-55.
64. Zhang D.D., Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol. Cell. Biol. 2003, 23:8137-8151.
65. Zhang D.D., Lo S.C., Sun Z., Habib G.M., Lieberman M.W., Hannink M. Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway. J. Biol. Chem. 2005, 280:30091-30099.
66. Zhang Y., Crouch D.H., Yamamoto M., Hayes J.D. Negative regulation of the Nrf1 transcription factor by its N-terminal domain is independent of Keap1: Nrf1, but not Nrf2, is targeted to the endoplasmic reticulum. Biochem. J. 2006, 399:373-385.